Common use of Conversion Restriction Clause in Contracts

Conversion Restriction. Notwithstanding anything to the contrary set forth in Section 5 of this Certificate of Designation, at no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that upon a holder of Series CC Preferred Stock providing the Company with sixty-one (61) days’ notice (pursuant to Section 5(i) hereof) (the “Waiver Notice”) that such holder would like to waive Section 7 of this Certificate of Designation with regard to any or all shares of Common Stock issuable upon conversion of Series CC Preferred Stock, this Section 7 shall be of no force or effect with regard to those shares of Series CC Preferred Stock referenced in the Waiver Notice.

Appears in 1 contract

Sources: Securities Issuance and Exchange Agreement (Pressure Biosciences Inc)

Conversion Restriction. Notwithstanding anything to the contrary set forth in Section 5 of this Certificate of Designation, at no time may a holder of shares of Series CC A Preferred Stock convert shares of the Series CC A Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99more than 9.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”)time; provided, however, that upon a holder of Series CC A Preferred Stock providing the Company with sixty-one (61) days’ days notice (pursuant to Section 5(i) hereof) (the “Waiver Notice”) that such holder would like to waive Section 7 of this Certificate of Designation with regard to any or all shares of Common Stock issuable upon conversion of Series CC A Preferred Stock, this Section 7 shall be of no force or effect with regard to those shares of Series CC A Preferred Stock referenced in the Waiver Notice.

Appears in 1 contract

Sources: Common Stock Exchange Agreement (VistaGen Therapeutics, Inc.)

Conversion Restriction. Notwithstanding anything to the contrary set forth in Section 5 of this Certificate of Designation, at no time may a holder of shares of Series CC B Preferred Stock convert shares of the Series CC B Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99more than 9.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”)time; provided, however, that upon a holder of Series CC B Preferred Stock providing the Company with sixty-one (61) days’ days notice (pursuant to Section 5(i5(g) hereof) (the “Waiver Notice”) that such holder would like to waive Section 7 of this Certificate of Designation with regard to any or all shares of Common Stock issuable upon conversion of Series CC B Preferred Stock, this Section 7 shall be of no force or effect with regard to those shares of Series CC B Preferred Stock referenced in the Waiver Notice.

Appears in 1 contract

Sources: Securities Exchange Agreement (Neoprobe Corp)